Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
40 hedge funds and large institutions have $10.6M invested in Oncternal Therapeutics, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 4 closing their positions.
299% more capital invested
Capital invested by funds: $2.67M → $10.6M (+$7.98M)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
5% more funds holding
Funds holding: 38 → 40 (+2)
52% less call options, than puts
Call options by funds: $27K | Put options by funds: $56K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.08M |
| 2 |
Morgan Stanley
New York
|
+$50K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$34.8K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$31.2K |
| 5 |
SIM
Spark Investment Management
New York
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$196K |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$60.7K |
| 3 |
Goldman Sachs
New York
|
-$28.6K |
| 4 |
RIM
Reliant Investment Management
Memphis,
Tennessee
|
-$16K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$14.3K |
ONCT Hedge Fund Activity: Q4 2014 in Review
40 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2014, worth a combined $10.6M — up 299% from $2.67M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ONCT positions and 4 closed out — a net gain of 3 holders — while 10 added to existing stakes and 7 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $7.08M. The largest seller was Oracle Investment Management, exiting entirely with an estimated $196K sold.
- 40 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2014, up from 38 in Q3 2014.
- Funds reported $10.6M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2014, up 299% quarter-over-quarter.
- 7 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2014 and 4 closed out, a net change of +3 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2014 was BVF Inc, an estimated $7.08M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2014 was Oracle Investment Management, an estimated $196K sold.
Based on aggregated 13F filings for Q4 2014.